Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0153470 (Spleen)
 4,015 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

5-lodo-2'-deoxyuridine (lUdR) significantly increases the total number of spleen cells on the fourth day after administration of 100 mg/kg in normal C3HeB/FeJ male mice. The number of splenic B-cells [cells sensitive to the cytotoxic activity of a rabbit antiserum to mouse F(ab)2, plus complement] increases on the same day. The number of T-cells (cells sensitive to the cytotoxic activity of a rabbit antiserum to mouse brain-associated theta antigen, plus complement) and of macrophages (adherent-phagocytic cells) does not increase. Spleen cells from lUdR-treated mice show heightened responsiveness in vitro to Escherichia coli lipopolysaccharide or concanavalin A on Day 4 and Days 5 to 6, respectively. The rate of clearance of i.v.-injected colloidal carbon is also increased for 3 days after lUdR. Thus, lUdR is able to functionally activate either T- or B-cells or macrophages, but only to increase the number of splenic B-cells.
 ...
PMID:Stimulatory effects of 5-lodo-2'-deoxyuridine on number and function of splenic B- and T-cells and of macrophages in C3HeB/FeJ mice. 108 70